Literature DB >> 18094166

Molecular characterization of feline immunodeficiency virus budding.

Benjamin G Luttge1, Miranda Shehu-Xhilaga, Dimiter G Demirov, Catherine S Adamson, Ferri Soheilian, Kunio Nagashima, Andrew G Stephen, Robert J Fisher, Eric O Freed.   

Abstract

Infection of domestic cats with feline immunodeficiency virus (FIV) is an important model system for studying human immunodeficiency virus type 1 (HIV-1) infection due to numerous similarities in pathogenesis induced by these two lentiviruses. However, many molecular aspects of FIV replication remain poorly understood. It is well established that retroviruses use short peptide motifs in Gag, known as late domains, to usurp cellular endosomal sorting machinery and promote virus release from infected cells. For example, the Pro-Thr/Ser-Ala-Pro [P(T/S)AP] motif of HIV-1 Gag interacts directly with Tsg101, a component of the endosomal sorting complex required for transport I (ESCRT-I). A Tyr-Pro-Asp-Leu (YPDL) motif in equine infectious anemia virus (EIAV), and a related sequence in HIV-1, bind the endosomal sorting factor Alix. In this study we sought to identify and characterize FIV late domain(s) and elucidate cellular machinery involved in FIV release. We determined that mutagenesis of a PSAP motif in FIV Gag, small interfering RNA-mediated knockdown of Tsg101 expression, and overexpression of a P(T/S)AP-binding fragment of Tsg101 (TSG-5') each inhibited FIV release. We also observed direct binding of FIV Gag peptides to Tsg101. In contrast, mutagenesis of a potential Alix-binding motif in FIV Gag did not affect FIV release. Similarly, expression of the HIV-1/EIAV Gag-binding domain of Alix (Alix-V) did not disrupt FIV budding, and FIV Gag peptides showed no affinity for Alix-V. Our data demonstrate that FIV relies predominantly on a Tsg101-binding PSAP motif in the C terminus of Gag to promote virus release in HeLa cells, and this budding mechanism is highly conserved in feline cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094166      PMCID: PMC2258934          DOI: 10.1128/JVI.02337-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  The C-terminal half of TSG101 blocks Rous sarcoma virus budding and sequesters Gag into unique nonendosomal structures.

Authors:  Marc C Johnson; Jared L Spidel; Danso Ako-Adjei; John W Wills; Volker M Vogt
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction.

Authors:  Ela Shai; Aaron Palmon; Amos Panet; Yitzhak Marmary; Yoav Sherman; Michael A Curran; Eithan Galun; Reba Condiotti
Journal:  Mol Ther       Date:  2005-07       Impact factor: 11.454

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Identification of the components of the murine T cell antigen receptor complex.

Authors:  L E Samelson; J B Harford; R D Klausner
Journal:  Cell       Date:  1985-11       Impact factor: 41.582

5.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15.

Authors:  F D Veronese; R Rahman; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

7.  Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats.

Authors:  J K Yamamoto; E Sparger; E W Ho; P R Andersen; T P O'Connor; C P Mandell; L Lowenstine; R Munn; N C Pedersen
Journal:  Am J Vet Res       Date:  1988-08       Impact factor: 1.156

8.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.

Authors:  R L Willey; D H Smith; L A Lasky; T S Theodore; P L Earl; B Moss; D J Capon; M A Martin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

9.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

10.  HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway.

Authors:  Juan Martin-Serrano; Scott W Eastman; Wayne Chung; Paul D Bieniasz
Journal:  J Cell Biol       Date:  2004-12-28       Impact factor: 10.539

View more
  29 in total

1.  Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction.

Authors:  Young Jun Im; Lillian Kuo; Xuefeng Ren; Patricia V Burgos; Xue Zhi Zhao; Fa Liu; Terrence R Burke; Juan S Bonifacino; Eric O Freed; James H Hurley
Journal:  Structure       Date:  2010-11-10       Impact factor: 5.006

2.  The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Ferri Soheilian; Kunio Nagashima; Eric O Freed
Journal:  Virology       Date:  2010-02-20       Impact factor: 3.616

3.  Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Mol Interv       Date:  2009-04

4.  Role of the feline immunodeficiency virus L-domain in the presence or absence of Gag processing: involvement of ubiquitin and Nedd4-2s ligase in viral egress.

Authors:  Arianna Calistri; Claudia Del Vecchio; Cristiano Salata; Michele Celestino; Marta Celegato; Heinrich Göttlinger; Giorgio Palù; Cristina Parolin
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

Review 5.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 6.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

7.  Feline immunodeficiency virus Gag is a nuclear shuttling protein.

Authors:  Iris Kemler; Dyana Saenz; Eric Poeschla
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

8.  Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Peter Y Mercredi; Sampson K Kyere; Justin Donlan; Tsutomu Murakami; Michael F Summers; Simon Cocklin; Eric O Freed
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  Functional replacement of a retroviral late domain by ubiquitin fusion.

Authors:  Anjali Joshi; Utpal Munshi; Sherimay D Ablan; Kunio Nagashima; Eric O Freed
Journal:  Traffic       Date:  2008-08-09       Impact factor: 6.215

10.  Defects in cellular sorting and retroviral assembly induced by GGA overexpression.

Authors:  Anjali Joshi; Kunio Nagashima; Eric O Freed
Journal:  BMC Cell Biol       Date:  2009-09-29       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.